Concurrent Intravenous and Intrathecal Nivolumab for Melanoma and Lung Cancer Patients With Leptomeningeal Disease

Phase 1, open-label, single-arm trial of nivolumab in leptomeningeal disease (LMD), melanoma and non-small cell lung cancer (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of adverse events at 2 years, Recommended dose of combined intrathecal (IT) and intravenous (IV) nivolumab at 28 days and 1 more. Started May 2018; status: active, not recruiting.